August 25, At 2pm, 2022Invitation to presentation of Acarix´s second quarter report

Past Events

May 10, 2022Naventus Corporate Finance & Partners, Healthcare Summit
March 16, 2022Redeye Theme: Artificial Intelligence Seminar 2022
Feb 18, 2022Capital Markets Day 2022: Acarix
About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based Coronary Artery Disease (CAD) rule-out.

The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing chest pain with suspected CAD and is designed to help reduce millions of unnecessary, invasive, costly diagnostic procedures. CADScor®System calculates a patient-specific CAD-score non-invasively in less than 10 minutes with 96% confidence.¹

Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).

Learn more
Contact Us

Please visit our contact page to get in touch.

Go to contact page
  1. US user manual v.12.5, prevalence 10,7%, algorithm version US3.2